Applications of recombinant Pichia pastoris in the healthcare industry

Brazilian Journal of Microbiology

Volumn 44, Issue 4, 2013, Pages 1043-1048

  Weinacker, Daniel ^a   Rabert, Claudia ^a   Zepeda, Andrea B ^a   Figueroa, Carolina A ^a   Pessoa, Adalberto ^b   Farías, Jorge G ^a  

^a UNIVERSIDAD DE LA FRONTERA   (Chile)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Heterologous expression system; Production; Recombinant protein; Scale up; Yeast

Indexed keywords

BIOTECHNOLOGY; GENETICS; HEALTH CARE COST; HUMAN; METABOLISM; MICROBIOLOGY; PHARMACEUTICS; PICHIA; PROCEDURES; TRANSGENIC ORGANISM;

BIOTECHNOLOGY; HEALTH CARE SECTOR; HUMANS; INDUSTRIAL MICROBIOLOGY; ORGANISMS, GENETICALLY MODIFIED; PICHIA; TECHNOLOGY, PHARMACEUTICAL;

EID: 84897395898     PISSN: 15178382     EISSN: 16784405     Source Type: Journal    
DOI: 10.1590/S1517-83822013000400004     Document Type: Review

References (32)

1. Bazan S. B, de Alencar Muniz Chaves A, Aires KA, Cianciarullo AM, Garcea RL, Ho PL, (2009) Expression and characterization of HPV-16 L1 capsid protein in Pichia pastoris. Arch Virol 154:1609-1617.
2. Borsi L., Castellani P, Balza E, Siri A, Pellecchia C, De SF, Zardi L (1986) Large-scale procedure for the purification of fibronectin domains. Anal Biochem 155:335-345.
3. Cereghino G. P, Cereghino JL, Ilgen C, Cregg JM (2002) Production of recombinant proteins in fermenter cultures of the yeast Pichia pastoris. Curr. Op Biotech 13:329-332.
4. Clare J. J, Rayment FB, Ballantine SP, Sreekrishna K, Romanos MA (1991) High-level expression of tetanus toxin fragment C in Pichia pastoris strains containing multiple tandem integrations of the gene. Biotechnology 9:455-460.
5. Coimbra E. C, Gomes FB, Campos JF, D'arc M, Carvalho JC, Mariz F. C, Jesus ALS, Stocco RC, Beçak W, Freitas AC (2011) Production of L1 protein from different types of HPV in Pichia pastoris using an integrative vector. Braz J Med Biol Res 44:1209-1214.
6. De Pourcq K, De Schutter K, Callewaert N (2010) Engineering of glycosylation in yeast and other fungi: current state and perspectives. Appl Microbiol Biotechnol 87:1617-1631.
7. Doyle L. A, Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2), Oncogene 22:7340-7358.
8. Ferrer-Miralles N, Domingo-Espin J, Corchero JL, Vazquez E, Villaverde A. (2009) Microbial factories forrecombinant pharmaceuticals. Microb Cell Fact 8:17.
9. Gurramkonda C., Polez S, Skoko N, Adnan A, Gäbel T, Chugh D, Swaminathan S., Khanna, N, Tisminetzky S, Rinas U (2010) Application of simple fed-batch technique to high-level secretory production of insulin precursor using Pichia pastoris with subsequent purification and conversion to human insulin. Microbial Cell Factories 9:31.
10. Higgins D. R, Cregg JM (1998) Methods in Molecular Biology: Pichia Protocols. Humana: Totowa, NJ.
11. Kaczmarek J., Castellani P, Nicolo G, Spina B, Allemanni G, Zardi L. (1994) Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int. J Cancer 59:11-16.
12. Li P., Anumanthan A, Gao XG, Ilangovan K, Suzara VV, Düzgünes N, Renugopalakrishnan V (2007) Expression of Recombinant Proteins in Pichia Pastoris. Appl Biochem Biotechnol 142:105-124.
13. Liccardi G., D'Amato M, D'Amato G (1996) Oleaceae pollinosis: a review. Int Arch Allergy Immunol 111:210-217.
14. Macauley-Patrick S, Fazenda ML, McNeil B, Harvey LM (2005) Heterologous protein production using the Pichia pastoris expression system. Yeast 22:249-270.
15. Mao Q., Conseil G, Gupta A, Cole SPC, Unadkata JD (2004) Functional expression of the human breast cancer resistance protein in Pichia pastoris. Biochemical and Biophysical Research Communications. 320:730-737.
16. Marazuela E. G, Hajek R, Villalba M, Barber D, Breiteneder H, Rodríguez R., Batanero E (2012) A non-allergenic Ole e 1-like protein from birch pollen as a tool to design hypoallergenic vaccine candidates. Molecular Immunology 50:83-90.
17. Martínez J. L, Liu L, Petranovic D, Nielsen J (2012) Pharmaceutical protein production by yeast: towards production of human blood proteins by microbial fermentation. Curr Op Biotech 21:1-7.
18. Marty C., Scheidegger P, Ballmer-Hofer K, Klemenz R, A Schwendener R. A (2001) Production of Functionalized Single-Chain Fv Antibody Fragments Binding to the ED-B Domain of the B-isoform of Fibronectin in Pichia pastoris. Protein Expression and Purification 21:156-164.
19. Mello A. PQ, da Silva IT, Saes Parra Abdallab D, Teixeira Damascenoa NR (2011) Electronegative low-density lipoprotein: Origin and impact on health and disease. Atherosclerosis 215:257-265.
20. Moll U. M, Wolff S, Speidel D, Deppert W (2005) Transcription independent pro-apoptotic functions of p53. Curr Opin Cell Biol 17:631-636.
21. Porro D., Gasser B, Fossati T, Maurer M, Branduardi P, Sauer M, Mattanovich D. (2011) Production of recombinant proteins and metabolites in yeasts. Appl Microbiol Biotechnol 89:939-948.
22. Rosenfeld S. A, Nadeau D, Tirado J (1999) Production and purification of recombinant hirudin expressed in the methylotrophic yeast Pichia pastoris. Methods Enzymol 306:154-169.
23. Sreekrishna K., Brankamp RG, Kropp KE, Blankenship DT, Tsay JT, Smith PL (1997) Strategies for optimal synthesis and secretion of heterologous proteins in the methylotrophic yeast Pichia pastoris. Gene 190:55-62.
24. Talos F., Petrenko O, Mena P (2005) Mitochondrially targeted p53 has tumor suppressor activities in vivo. Cancer Res 65:9971-9981.
25. Walsh G., Jefferis R (2006) Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 24:1241-1252.
26. White J. F, Bernstein DI (2003) Key pollens in North America. Ann. Allergy Asthma Immunol 91:425-435.
27. Willis A. C, Chen X (2002) The promise and obstacle of p53 as a cancer therapeutic agent. Curr Mol Med 2:329-345.
28. Xu J., Liu Y, Yang Y, Bates S, Zhang JT (2004) Characterization of oligomeric human half ABC transporter ABCG2/BCRP/MXR/ ABCP in plasma membranes. J Biol Chem 279:19781-19789.
29. Yan H., Liu N, Zhao Z, Zhang X, Xu H, Shao B, YanW(2012) Expression and purification of human TAT-p53 fusion protein in Pichia pastoris and its influence on HepG2 cell apoptosis. Biotechnol Lett 34:1217-1223.
30. Zalewski A., Macphee C (2005) Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler. Thromb Vasc Biol 25:923-931.
31. Zardi L., Carnemolla B, Siri A, Petersen TE, Paolella G, Sebastio G, Baralle FE (1987) Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J 6:2337-2342.
32. Zhang F., Dong Li, Cai M, Shen J, Wang Y (2006) Heterologous expression of lipoprotein-associated phospholipase A2 in different expression systems. Protein Expression and Purification 48:300-306.